Figure 6.

ROME expression increases cell motility and chemotaxis in vitro. A, TC-71 cells stably overexpressing ROME demonstrated increased wound closure compared with that of a control cell line, and TC-71 cells with ROME KO by CRISPR/Cas9 demonstrated decreased wound closure compared with that of WT cells in scratch assays. At least two independent experiments were performed, and average wound closure with SEM was quantified. Statistical significance was calculated by an unpaired t test (two-tailed). B–E, Compared with EV control cells, A4573, TC-71, and Hs746.T cells stably expressing ROME presented increased chemotaxis in Boyden chamber assays. F, CHLA-10 cells with ROME KO via CRISPR/Cas9 showed decreased chemotaxis compared with that of WT cells. G–I, ROME KO (TC-71) or knockdown (769-P and Hs746.T) decreased the chemotaxis of cancer cells. J and K, Rescue of ROME expression by an exogenous vector restored chemotaxis in both CHLA-10 and TC-71 cells. At least two independent experiments with three biological replicates were performed for each Boyden chamber assay. Statistical significance was calculated by an unpaired t test (two-tailed).